+1 (424) 212-4087

OHSS in IVF: A Complete Guide to Ovarian Hyperstimulation Syndrome, Risk Factors, Prevention, and Warning Signs in Torrance

Most people who start IVF are focused on the laboratory: sperm, eggs, embryos, and the transfer. But long before any of that happens, the ovaries must be stimulated to mature several eggs in a single cycle, and it is this step — not the lab work — that carries a well-known risk called ovarian hyperstimulation syndrome (OHSS). For patients in Torrance and the South Bay, OHSS is one of the most common reasons a stimulation plan is adjusted, a trigger shot is changed, or a fresh transfer is postponed. Understanding it in advance turns a frightening surprise into a monitored, manageable part of care.

This guide is written for patients who want to understand what OHSS is, who is most likely to develop it, how modern monitoring and trigger strategies are designed to prevent it, what the warning signs are, and how it is treated if it occurs. It applies whether eggs are being collected for IVF at Incinta Fertility or for egg freezing in Torrance, because the stimulation phase is the same in both. One boundary applies throughout: every number and range here is a population-level figure drawn from published research and professional guidance (ASRM, NICHD, MedlinePlus). It is not a prediction about your body, your cycle, or your outcome, and it is not a clinic-specific result, guarantee, or promise. The plan that is right for you comes from your own history, reserve, and response, discussed with your physician.

1. What OHSS Is — and Where It Fits in Treatment

Ovarian hyperstimulation syndrome is an exaggerated response to the medicines used to make eggs grow, especially the injectable gonadotropins given during IVF. The American Society for Reproductive Medicine (ASRM) describes it as a condition in which a large number of follicles develop and estradiol levels rise high, causing fluid to leak into the abdomen and sometimes the chest. It is not an infection, not a reaction to the transfer, and not a sign that anything was done wrong. It is a dose-and-response phenomenon: the ovaries over-respond to stimulation.

The risk belongs to the stimulation and trigger part of the cycle — the days before egg retrieval — not to the laboratory or the transfer. That is why so much of OHSS prevention happens before the procedure: in the workup, the protocol choice, the daily monitoring, and the trigger decision. A whole-cycle overview is in our step-by-step IVF journey guide. Seeing where OHSS sits on the timeline makes it easier to understand why your team watches the ovarian response so closely, and why a “freeze-all” decision is often made for safety rather than convenience.

Because the stimulation phase is identical, the OHSS conversation applies just as much to egg preservation as it does to IVF; our egg preservation guide describes that pathway. OHSS is common, usually mild, and — with the monitoring standard used in a supervised cycle — highly manageable. The goal of this article is not to alarm you, but to make the safety steps visible so that you can take part in them.

2. Why It Happens: Follicles, Estrogen, and the Fluid Shift

During stimulation, injectable gonadotropins recruit a cohort of follicles rather than the single egg a natural cycle would produce. ASRM notes that generally 8 to 14 days of stimulation are required before the eggs are ready. As follicles grow, they produce estradiol. In an over-response, the combination of many follicles and high estradiol sets off a change in blood vessels that makes them more permeable, so fluid moves out of the bloodstream and into the abdominal cavity — and, in more severe cases, around the lungs.

That fluid shift explains the hallmark features of OHSS: enlarged ovaries, abdominal bloating and swelling, weight gain from retained fluid, nausea, and, when fluid collects around the lungs, shortness of breath. ASRM states that the ovaries are enlarged in all cases of OHSS, and that ovarian size is a marker of the degree of the condition. A transvaginal or abdominal ultrasound can measure both ovarian size and the amount of fluid that has collected, which is why imaging — not how you feel alone — guides the assessment.

It is important to understand that an over-response is a biological reaction, not a personal failing and not simply a matter of “too much medication.” The same dose can produce very different responses in different people. That is why your team reads your age, AMH, antral follicle count, and prior response together before choosing a starting dose — the subject of our AMH and ovarian reserve guide. Predicting the response as accurately as possible is the first and most powerful form of prevention.

3. How Common Is OHSS? Reading the Numbers Honestly

The most quoted figures come from ASRM. Its Assisted Reproductive Technologies booklet states that up to 30% of women undergoing ovarian stimulation have a mild case of OHSS that can be managed with over-the-counter pain relief and a reduction in activity, while up to 2% develop severe OHSS — with excessive weight gain, fluid in the abdomen and chest, electrolyte abnormalities, over-concentration of the blood, and, in rare cases, blood clots, kidney failure, or death.

ASRM’s dedicated OHSS fact sheet (revised 2023) puts the mild figure even more plainly: one out of three people with ovaries have symptoms of mild OHSS during controlled ovarian stimulation for IVF. Read these numbers as ranges for groups of patients, not as your personal odds. A mild case is common and usually short-lived; a severe case is uncommon, and much of modern protocol design is aimed at making it rarer still. Ask for ranges tied to your own test results rather than a generic figure.

The same booklet notes that up to 20% of cycles may be cancelled before egg retrieval, and that a cycle is occasionally cancelled specifically to reduce OHSS risk. A cancellation is a medical decision made to protect you, not a failure, and it often leads to a better-matched protocol next time. If you are anxious about numbers, our IVF success-rate guide explains how to read clinic statistics without drawing the wrong personal conclusion.

4. Mild, Moderate, and Severe: What the Grades Mean

ASRM classifies OHSS as mild, moderate, or severe. In mild OHSS, symptoms may include mild abdominal bloating, nausea, and weight gain due to fluid, and the ovaries are enlarged. These symptoms can usually be managed with over-the-counter pain relief and reduced activity. This is the “up to 30%” or “one in three” group described above — uncomfortable, but generally short-lived and treated at home with monitoring.

In moderate OHSS, the same symptoms are more pronounced, fluid accumulates within the abdominal cavity, and gastrointestinal symptoms may occur. This grade typically calls for closer monitoring, more frequent office visits, and active symptom management rather than simple watchful waiting. Your team may adjust medication, recommend drainage if fluid becomes bothersome, and watch carefully for signs that the condition is progressing.

In severe OHSS, ASRM describes vomiting with an inability to keep liquids down, significant discomfort from abdominal swelling, shortness of breath, and blood clots that can form in the legs. Severe cases are the “up to 2%” group and may require hospital care. Grading is clinical: your team uses symptoms, ultrasound findings, and blood tests — not a single number — to decide where you sit. Our fertility testing guide explains the baseline measurements that feed into that judgment.

5. Who Is at Risk — and Who Is Not

ASRM’s fact sheet names the clearest risk factors: a high AMH level and polycystic ovary syndrome (PCOS) — the fact sheet uses updated terminology, “polyendocrine metabolic ovarian syndrome,” formerly PCOS. Both are associated with a high follicle count and an exuberant response to stimulation. If you have PCOS, our PCOS and fertility guide and the AMH interpretation guide are useful background before your protocol visit.

Just as important, ASRM states that individuals with low ovarian reserve are not at risk for OHSS. That is a useful antidote to the fear that “everyone gets it.” Patients with diminished ovarian reserve or POI are generally counseled about a lower egg yield, not about over-response. Age and reserve shape the plan in opposite directions, which is why our age and fertility guide is often read alongside this one.

A prior episode of OHSS, a very high antral follicle count, and a strong past response to stimulation are additional reasons your team may start low and adjust carefully. Endometriosis or prior ovarian surgery can change the picture in other ways. Bring your prior cycle records: how you responded last time is one of the best predictors of how you will respond next time, and it lets the team plan prevention instead of reacting.

6. Early vs. Late OHSS: Why Timing Matters

OHSS is often described by when it appears. ASRM notes that symptoms usually start a few days after ovulation — or, in a stimulated cycle, around the trigger. This “early” form is tied to the stimulation and trigger itself and tends to track the follicle number and estradiol level your team has been following. Monitoring in the days right before retrieval is designed to anticipate it and, where possible, to prevent it before the procedure happens.

There is also a “late” form, in which symptoms appear after egg retrieval and are amplified by the hormones of an early pregnancy. ASRM states that if pregnancy occurs, OHSS can worsen or last longer; pregnant individuals often continue to have symptoms for two to three weeks or more after a positive pregnancy test, then gradually improve, with the rest of the pregnancy unaffected. This is the key reason the transfer decision and OHSS risk are so closely linked.

Both forms share a driver: hCG, whether given as the injection that completes egg maturation or produced naturally by an early pregnancy. That single fact explains two of the main prevention strategies you will hear about — using an agonist trigger instead of hCG, and avoiding a fresh transfer when OHSS risk is high. Our embryo transfer guide covers the fresh-versus-frozen decision in detail.

7. How Monitoring Is Designed to Catch OHSS Early

Prevention starts with information. ASRM describes transvaginal ultrasound examinations to follow follicle development and blood tests to measure the response to stimulation — estradiol rises as follicles grow, while progesterone typically stays low until after ovulation. The team reads those signals together, then adjusts the dose, adds a suppression drug, or decides that the eggs are close to ready. No single value is interpreted in isolation.

Monitoring is not a fixed schedule; it intensifies as follicles grow, and patients should expect frequent early-morning visits in the days before retrieval. A rapid estradiol rise, a very high follicle count, or new symptoms such as marked bloating can all prompt a change before the patient ever reaches the procedure room. This is one practical reason a closely supervised, in-person cycle is safer than a loosely monitored one, and why travel plans need buffer days.

When the response is stronger than expected, the team can lower the dose, add a GnRH antagonist, trigger with an agonist, or cancel the cycle outright. ASRM notes that a cycle may be cancelled to reduce OHSS risk. Patients traveling for treatment should build flexibility into their plans; our guide to timing treatment around egg retrieval explains the practical side of staying nearby during monitoring.

8. Prevention Step 1: Individualized Dosing and Protocols

The first prevention lever is the starting dose. ASRM’s fact sheet states that reducing the dose of ovarian stimulation medications may reduce OHSS risk. Dosing is individualized from the workup — age, AMH, antral follicle count, PCOS status, and prior response — and then tuned to the monitoring data. A fertility workup is therefore not a formality; it is the basis of a safer stimulation plan.

Incinta Fertility describes a mild ART (gentler stimulation) approach among its options. The idea is to use lower medication doses to retrieve fewer but high-quality eggs, which can mean less discomfort, a lower OHSS risk, and reduced medication cost. It is not right for everyone: patients with lower reserve may need more cycles to accumulate enough embryos, so the “gentlest” protocol is not automatically the best one. Your physician chooses based on age, reserve, and goals, not on a preference for one label.

The right framing is that OHSS risk is managed, not eliminated. A high responder may need a cautious, low-dose or antagonist protocol from day one; a low responder may need a standard dose and reassurance that over-response is unlikely. Our nutrition and lifestyle guide covers the habits that are reasonable to control during stimulation, while being clear about what medication and biology determine.

9. Prevention Step 2: The Trigger Shot — Agonist Trigger and hCG

When the follicles are judged ready, a “trigger” medication completes the final stage of egg maturation. In the classic protocol described by ASRM, human chorionic gonadotropin (hCG) replaces the natural LH surge, and eggs are retrieved 34 to 36 hours later. But hCG is also the strongest driver of the fluid shift behind OHSS — it is the same hormone an early pregnancy produces, which is why trigger choice matters so much.

ASRM’s OHSS fact sheet states that using leuprolide (a GnRH agonist) instead of hCG as the final trigger can prevent OHSS. An agonist trigger produces a shorter hormonal surge and is often paired with a freeze-all approach, because it does not support the uterine lining well enough for a fresh transfer in the same cycle. This is a sophisticated, evidence-based option for high responders, not a universal switch — your team weighs it against your specific situation.

ASRM also notes that a medicine called cabergoline can reduce fluid accumulation and is part of the risk-reduction toolkit. The exact combination — dose, antagonist, trigger type, and any add-on medication — belongs to your team. Our egg retrieval guide explains the trigger window and why its timing is treated as non-negotiable, especially for patients coordinating travel from outside the South Bay.

10. Prevention Step 3: Freeze-All and Delaying Transfer

The third prevention lever is deciding what to do with the embryos. ASRM’s fact sheet states that if OHSS develops, avoiding immediate pregnancy by freezing eggs or embryos for transfer at a later time can help OHSS resolve more quickly and keep it from progressing. This is the medical logic behind a “freeze-all” cycle, and it is why the transfer plan is often made with OHSS risk in mind from the start.

The reason is the late form of OHSS described earlier: a fresh transfer can lead to pregnancy, and pregnancy hormones can make OHSS worse or last longer. By freezing all suitable embryos and transferring in a later, unstimulated cycle, the team removes that amplifying factor. Incinta’s IVF page notes that embryos are generally transferred on day three or day five, and that a freeze-all may be chosen for medical reasons such as OHSS risk.

Patients sometimes read a freeze-all as a setback. It is better understood as a safety decision that separates the stimulated cycle from a carefully prepared uterine environment in a later frozen embryo transfer. If preimplantation genetic testing is also planned, that delay can be used productively. A freeze-all protects your health without giving up the chance of pregnancy.

11. Recognizing the Symptoms: What Is Normal and What Is Not

After stimulation and retrieval, some bloating, mild abdominal discomfort, and a feeling of fullness are common: the ovaries remain enlarged for a while, and mild cramping on retrieval day usually settles by the next day. ASRM notes that mild OHSS symptoms include mild abdominal bloating, nausea, and weight gain due to fluid. Separating this from a problem is a matter of trajectory, not any single sensation.

Symptoms that are stable or fading are different from symptoms that escalate: worsening abdominal pain, rapidly increasing swelling, vomiting, reduced urination, or shortness of breath. ASRM lists difficulty tolerating fluids, abdominal swelling, and decreased urination among the signs that should prompt a call. When in doubt, call — clinical teams would much rather triage a harmless symptom than manage a preventable complication that was left overnight.

Waiting through a stimulation cycle with new physical sensations can be stressful, and anxiety can make normal discomfort feel alarming. Our fertility stress and emotional support guide offers practical coping strategies, and keeping your team’s after-hours number within reach is part of a calm, prepared plan. Knowing the red-flag list below does more for peace of mind than vague reassurance, because it tells you exactly when to act.

12. The Red-Flag List: When to Call the Clinic or Go to the ER

ASRM’s fact sheet gives a specific list of symptoms that should be reported to your doctor. These include difficulty breathing; continued vomiting or nausea; difficulty tolerating fluids; abdominal swelling; decreased urination; weight gain of more than three pounds in two days; sudden onset of abdominal pain; and other symptoms such as facial numbness, weakness, lower-extremity swelling, or redness. Report these promptly rather than waiting to see if they pass.

Each item maps to a complication: reduced urination and rapid weight gain reflect fluid shifts and dehydration; shortness of breath can mean fluid around the lungs; leg swelling or redness can signal a clot; severe abdominal pain can reflect ovarian torsion or rupture. ASRM warns that a standard pelvic exam is generally not recommended when OHSS is present, because the ovaries are enlarged and present cysts may burst under pressure — another reason to let your team decide the examination.

Severe OHSS — continued vomiting, severe abdominal swelling, shortness of breath, inability to drink fluids, or abnormal lab results — may require hospitalization for intensive monitoring and treatment. MedlinePlus also advises patients to contact their provider promptly after IVF if they develop fever, pelvic pain, heavy bleeding, or blood in the urine. Keep the after-hours number where you can actually find it at 2 a.m.; knowing whom to call is part of a safe cycle.

13. How OHSS Is Treated: From Self-Care to Hospital Care

Most OHSS is managed in an outpatient setting. ASRM describes office visits for ultrasound to measure the ovaries and abdominal fluid, plus blood tests. Decreased activity and drinking plenty of electrolyte-rich fluids are recommended, and medicines for nausea are available. Careful monitoring and frequent visits are the backbone of treatment, not a single cure, and symptoms often improve steadily once the hormonal driver settles.

If fluid is in the abdomen, ASRM states that drainage (paracentesis) can provide significant relief in most cases, and that more than one drainage is occasionally helpful. Cabergoline can also reduce fluid accumulation. These are practical measures that relieve symptoms while the condition resolves; they are performed by your clinical team, not something to research and attempt on your own. Nutrition and hydration support, described in our nutrition and lifestyle guide, can help you stay comfortable.

If OHSS does not improve with outpatient care, treatment may continue in the hospital with close monitoring, intravenous fluids, medicines for nausea, removal of abdominal fluid, and other supportive therapy as needed. ASRM notes that there is rarely a need for hospitalization; when severe complications such as blood clots or kidney problems arise — described as rare — they are treated urgently. Our guide to what follows the transfer covers the recovery context around these decisions.

14. Questions Worth Asking Your Team Before Stimulation

A stimulation cycle feels calmer when the safety plan has been named out loud. Consider asking the following at your workup or protocol review:

  • Based on my AMH, follicle count, and history, am I likely to be a high responder — and what is my OHSS risk?
  • Which stimulation dose and protocol are you choosing for me, and why?
  • Will you use an hCG trigger or an agonist trigger, and what would make you choose one?
  • Under what circumstances would you cancel this cycle or convert it to freeze-all?
  • How often will I have monitoring visits, and what values would change my plan?
  • Which symptoms should prompt a phone call, and which require the emergency department?
  • What is your after-hours number, and who covers it on weekends?
  • If I become pregnant, how will you adjust my follow-up given the OHSS risk?

None of these questions asks for a guarantee; they ask for a plan, and a good clinical team will welcome them. If an answer is “we’ll see on the day,” ask who will tell you and when. Clarity about communication is often the difference between an anxious cycle and a manageable one. Patients with a history of implantation failure or recurrent pregnancy loss may have additional questions, and the same principle applies.

15. Frequently Asked Questions

What exactly is OHSS?

OHSS (ovarian hyperstimulation syndrome) is an exaggerated response to the medications used to make eggs grow during IVF or egg freezing. Many follicles develop and estrogen rises, causing fluid to leak into the abdomen and, in more severe cases, the chest. The ovaries enlarge. It is a biological over-response, not an infection or a sign that the cycle was mishandled.

How common is OHSS?

According to ASRM, up to 30% of women undergoing ovarian stimulation have a mild case, and one in three people have mild symptoms during stimulated IVF cycles. Severe OHSS is much less common, affecting up to 2%. These are population-level figures, not predictions for any individual.

What are the warning signs that need urgent attention?

ASRM lists difficulty breathing, continued vomiting or nausea, trouble tolerating fluids, abdominal swelling, decreased urination, weight gain of more than three pounds in two days, sudden abdominal pain, and facial numbness, weakness, leg swelling, or redness. Report these to your team promptly.

Can OHSS be prevented?

Risk can be substantially lowered, though not always eliminated. Strategies include individualized, lower stimulation doses; a GnRH agonist trigger instead of hCG; medications such as cabergoline; close ultrasound and blood monitoring; and freezing eggs or embryos to avoid pregnancy-related hormones in the same cycle.

Does a high AMH mean I will get OHSS?

A high AMH is one of the clearest risk factors, especially alongside PCOS, because it suggests a strong follicle response. It does not mean OHSS is certain. Conversely, ASRM states that people with low ovarian reserve are not at risk. Your team reads AMH together with your follicle count, age, and prior response.

How long does OHSS last?

ASRM says symptoms usually begin a few days after ovulation and resolve within two weeks unless pregnancy occurs. If you are pregnant, symptoms often continue for two to three weeks or longer after a positive test, then gradually fade; the rest of the pregnancy is not affected.

Will OHSS affect my chances of pregnancy?

Mild OHSS generally does not change the outlook for a future cycle. The main concern is safety during the current one. If OHSS risk is high, freezing all embryos and transferring in a later cycle protects your health without giving up the chance of pregnancy.

Is a fresh embryo transfer safe if I have OHSS?

When OHSS is significant, a fresh transfer is usually avoided because pregnancy hormones can make OHSS worse or longer-lasting. Your team may recommend a freeze-all cycle and a frozen embryo transfer in a later, unstimulated cycle. This is a safety decision, not a loss of opportunity.

For authoritative background on OHSS and ovarian stimulation, see the ASRM patient fact sheet Ovarian Hyperstimulation Syndrome (OHSS) and the ASRM booklet Assisted Reproductive Technologies. Plain-language references are available from MedlinePlus and NICHD.

Medical and informational disclaimer: This article is general educational information, not medical advice, and it is not a substitute for evaluation by a qualified reproductive endocrinology specialist. Any statistics, percentages, or ranges mentioned are population-level figures from published research, guidelines, and authoritative sources (such as ASRM, NICHD, MedlinePlus, and professional society guidance); they are typical ranges for groups, not predictions about any individual, and they are not clinic-specific results, guarantees, or quotes. Medication choices, stimulation dosing, trigger type, monitoring frequency, the freeze-all decision, symptom management, and all costs must be discussed directly with your medical team in a written, individualized assessment before any decision.

Incinta Fertility Center — Fertility Clinic Torrance & South Bay, California

By the Incinta Editorial Team · Medically reviewed by the Incinta Review Team

Call us: +1 (424) 212-4087